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Although small-cell lung cancer (SCLC) generally shows an excellent response to initial 
chemotherapy, most patients finally relapse and salvage chemotherapy is considered. 
Usually, the response to salvage chemotherapy significantly differs between sensitive 
and refractory relapse. Sensitive relapse is relatively chemosensitive and re-challenge 
with the same drugs as used in the initial chemotherapy has been used historically, while 
refractory relapse is extremely chemoresistant and its prognosis has been abysmal. To 
date, a number of clinical trials have been carried out for relapsed SCLC; however, the 
number of randomized trials is quite limited. At present, topotecan is the only drug 
approved by the US Food and Drug Administration for relapsed SCLC, and is 
considered the standard second-line chemotherapy in many countries. More recently, 
amrubicin has also shown more favorable antitumor activity, and is the most promising 
at present. Unfortunately, targeted agents have failed to demonstrate effectiveness for 








Small-cell lung cancer (SCLC) is strongly associated with tobacco smoking. In recent 
years, the incidence of SCLC has been gradually decreasing according to the decrease 




 Good sensitivity to chemotherapy and radiotherapy is a feature of SCLC and 
most patients respond to initial chemotherapy or chemoradiotherapy; however, the 
majority of patients develop recurrence and the prognosis of such patients is reportedly 
2–4 months.2 
 In predicting the efficacy of salvage chemotherapy, both the response and the 
duration of the response to initial chemotherapy are important.
3,4
 Based on these factors, 
relapsed or refractory SCLC has been classified into 2 groups: patients who respond to 
the initial chemotherapy and relapse more than 2 or 3 months after the completion of 
chemotherapy are considered to be ‘sensitive relapse’ patients, while patients whose 
tumor is stable or progresses during the initial chemotherapy or who have a recurrence 
within 2 or 3 months after the completion of chemotherapy are considered to be 
‘refractory relapse’ patients.5  
  Previous studies have reported the effectiveness of re-challenge with the same 
drugs used in the initial chemotherapy and it has been justified for sensitive relapse
5-7
; 
however, refractory relapse is exceedingly chemo-resistant, and response rates of less 
than 10% are usually attained with single-agent chemotherapy in those patients.
8
  
Consequently, although a number of chemotherapy regimens have been evaluated in 
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clinical trials and some have shown promising antitumor activity, no standard 
chemotherapy had been established for relapsed SCLC until recently. Currently, 
topotecan is the only drug approved by the US Food and Drug Administration for 
relapsed SCLC, and is considered the standard second-line chemotherapy in many 
countries.
9
 More recently, amrubicin has also shown promising antitumor activity in this 
setting
10,11
; however, to date it is not approved outside Japan. 
 
Cytotoxic agents 
Single-agent chemotherapy (except for topotecan and amrubicin) 
Etoposide was composed in 1966 and has been used for the treatment of SCLC. It was 
initially evaluated in the second-line setting because the combination of 
cyclophosphamide, doxorubicin, and vincristine (CAV) was the standard first-line 
regimen for SCLC at the time. In the study conducted by Evans et al., 18 refractory 
relapse patients were treated with etoposide. Fourteen patients were evaluable for 
response, and only 1 partial response (PR) was observed.
12
 Wolff et al. evaluated the 
efficacy of etoposide at three different doses in relapsed SCLC: 300, 600, and 900 
mg/m
2
. Twenty-six, 27, and 26 patients were treated at each dose level; however, only 4 
patients achieved PR and the response rate was 6%.
13
 These results suggest that 
single-agent etoposide has only limited activity in the second-line setting. 
 Irinotecan is a hemisynthetic product of camptothecin and shows strong 
antitumor activity by inhibiting DNA topoisomerase I. In the first-line setting, the Japan 
Clinical Oncology Group (JCOG) conducted a randomized phase III study comparing 
cisplatin-etoposide (PE) with cisplatin-irinotecan (PI) in patients with extensive disease 





 Although subsequent studies conducted in the US failed to 
reproduce the results of the JCOG study, the efficacy of PE and PI was almost identical 
and both are thought to be standard first-line regimens for ED-SCLC.
15,16
 In the 
second-line setting, Masuda et al. conducted a phase II study of irinotecan. Fifteen 
patients were given 100 mg/m
2
 of irinotecan every week and a response rate of 47% 
was observed.
17
 In the randomized phase II study comparing irinotecan alone with the 
combination of irinotecan and gemcitabine, however, no partial or complete response 
was observed (n=31).
18
 In the study, 64% of patients had a refractory relapse. Although 
single-agent of irinotecan is promising in the second-line setting, its efficacy is limited 
for refractory relapse. 
 Paclitaxel promotes the assembly of tubulin into microtubules and renders the 
microtubule resistant to depolymerization, interfering with mitosis, and has 
demonstrated an antitumor effect against SCLC in both preclinical and clinical 
studies.
19,20
  In the phase II study conducted by Smit et al., 24 heavily pretreated SCLC 
patients were treated with paclitaxel, 175 mg/m
2
 intravenously every 3 weeks. Of 24 
patients, 15 had previously received more than 2 regimens, and a 29% response rate was 
achieved.
21
 Although it may be active against drug-resistant SCLC, there is insufficient 
clinical evidence to use paclitaxel routinely in the clinical setting.  
 Gemcitabine, a novel nucleoside analogue similar in structure to cytosine 
arabinoside (ara-C), is a pyrimidine antimetabolite, and its mechanism of action has 
been well characterized. In the phase II study conducted by Hoang et al., 27 pretreated 
SCLC patients were treated with 1250 mg/m
2
 of gemcitabine intravenously on days 1 
and 8, every 3 weeks. Of 27 patients, 15 were sensitive and 12 had a refractory relapse. 
There were no PR and only 3 patients achieved stable disease (SD). The authors 
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concluded that single-agent of gemcitabine had only limited activity against previously 
treated SCLC.
22 
 Pemetrexed, a multitargeted antifolate agent, has been approved for 
non-small-cell lung cancer (NSCLC) and malignant mesothelioma worldwide. Based on 
an in vitro study which showed growth inhibition of the SCLC cell line
23
, Jalal et al. 
carried out a phase II study of pemetrexed in SCLC patients. Pemetrexed was 
administered at 500 mg/m
2 
intravenously every 3 weeks for up to 6 cycles. Twenty 
sensitive relapse and 23 refractory relapse patients were enrolled; however, only 1 
patient had PR and 3 had SD in each group.
24
 In the study conducted by Gronberg et al., 




was given with the supplementation of vitamin B12 
and folic acid. Among 34 patients who received the study treatment, only 1 patient (3%) 
achieved PR and 29 (85%) had progressive disease (PD).
25
 Pemetrexed was also 
investigated in the first-line setting. In the study, chemotherapy-naïve patients with 
ED-SCLC were randomized to receive either carboplatin-pemetrexed or 
carboplatin-etoposide. The response and survival of carboplatin-pemetrexed was 
significantly inferior to those of carboplatin-etoposide.
26
 Thus, further exploration of 
pemetrexed is not warranted in SCLC. 
 Picoplatin is a cisplatin analog designed to avoid the development of platinum 
resistance, and preclinical data demonstrated that picoplatin overcomes platinum 
resistance in lung cancer. Eckardt et al. conducted a phase II study of picoplatin in 
patients with platinum-refractory or –resistant, relapsed SCLC. Seventy-seven patients 
were treated with picoplatin and 72 were assessable for response. There were 3 PRs 
(4%), 33 SDs (43%), and 36 PDs (47%).
27
 A phase III study comparing picoplatin with 
best supportive care (BSC) is ongoing. 
7 
 
 The efficacy data of single-agent chemotherapy except for topotecan and 





In the era of CAV, the most intensively investigated second-line regimen was PE. In the 
study conducted by Evans et al., 15 of 34 evaluable patients had PR (response rate: 
44%).
12
 In their subsequent study, 78 patients were treated with PE and 43 achieved a 
marked response (response rate: 55%), including 6 complete responses (CR).
34





 response rates were observed for PE; however, there is an 
issue that the percentages of sensitive and refractory relapse were not presented in those 
studies. In fact, only a 12% response rate was observed in the study conducted by Batist 
et al.
37
 In the study, the median time since the last chemotherapy was 3 weeks (range, 
1–24), suggesting that the majority of patients had refractory relapse. Porter et al. 
reported a 52% response rate for 29 refractory relapse; however, the definition of 
‘refractory’ in the study was not clear.38 Recently, in a randomized phase II study 
comparing PE with the combination of cisplatin, etoposide, and carboplatin, a 19% 
response rate was noted for refractory relapse in the PE arm.
39 
The platin-etoposide 
combination seems active in sensitive relapse; however, its efficacy is not evident in 
refractory relapse.  
Irinotecan has been extensively investigated in combination with both cisplatin 
(PI) and carboplatin (CI). Ando et al. examined weekly PI. Twenty-five patients who 
had previously been treated with etoposide and a platinum-containing regimen were 
enrolled, and 20 patients achieved PR (response rate: 80%).
40
 In this study, even among 
16 refractory relapse patients, 13 PR (81%) were observed. Naka et al. conducted a 
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phase II study of weekly CI, which consisted of an area under the curve (AUC) = 2 of 
carboplatin and 50 mg/m
2
 of irinotecan on days 1, 8, and 15 every 4 weeks. In 
refractory relapse, 3 of 13 patients had a PR (23.1%), and in sensitive relapse, 6 of 16 
had a PR (37.5%), and there was no statistical significance in the response rate between 
the two.
41
 In the study conducted by Hirose et al., patients were treated with CI, AUC = 
5 of carboplatin on day 1 and 50 mg/m
2
 of irinotecan on days 1 and 8 every 3 weeks. Of 
22 evaluable patients, 15 achieved PR, with an overall response rate of 68%. Response 
rates in sensitive and refractory relapse were 92% and 33%, respectively.
42
 Masuda et al. 
evaluated the effectiveness of combination chemotherapy of etoposide-irinotecan. In 
their study, 25 patients were treated with 80 mg/m
2
 of etoposide on days 1 to 3 and 70 
mg/m
2
 of irinotecan on days 1, 8, and 15 every 4 weeks, and the response rates were 
75% for refractory relapse and 70% for sensitive relapse, respectively.
43
 The 
combination of irinotecan and gemcitabine was also investigated in several studies; 
however, the response rates for refractory relapse were not promising.
18,44,45
  
Three-drug combination of cisplatin, etoposide, and irinotecan (PEI) was 
investigated separately for both sensitive and refractory relapse. Goto et al. treated 40 
sensitive relapse patients with the PEI regimen, which consisted of 25 mg/m
2
 of 
cisplatin weekly for 9 weeks, 25 mg/m
2
 of etoposide for 3 days in weeks 1, 3, 5, 7, and 
9, and 90 mg/m
2
 of irinotecan in weeks 2, 4, 6, and 8 with granulocyte 
colony-stimulating factor support. Five CRs and 26 PRs were observed, and the overall 
response rate was 78%. The median survival time (MST) and 1-year survival rate were 
11.8 months and 49%, respectively.
46
 Grade 3/4 leucocytopenia, neutropenia, and 
thrombocytopenia were observed in 55, 73, and 33% of the patients, respectively. 
Non-hematologic toxicities were mild and transient in all patients. No treatment-related 
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deaths were observed. Considering that this regimen also achieved a 70% response rate 
in refractory relapse
47
, PEI warrants further investigation in the second-line setting. 
 The combination of carboplatin and paclitaxel (CP) was evaluated for 
refractory relapse in 2 studies. In the study conducted by Groen et al., 35 refractory 
relapse patients who were resistant to cyclophosphamide, doxorubicin, and etoposide 
were treated with CP consisting of 175 mg/m
2
 of paclitaxel on day 1 and AUC = 7 of 
carboplatin on day 1 every 3 weeks. There were 2 CRs and 23 PRs, and the overall 
response rate was 73%. MST and the 1-year survival rate was 31 weeks and 9%, 
respectively.
48
 In the other study conducted by Kakolyris et al., 22 refractory relapse 
patients were treated with CP consisting of 200 mg/m
2
 of paclitaxel on day 1 and AUC 
= 6 of carboplatin on day 1 every 3 weeks, with a 25% response rate.
49 




Topotecan and Amrubicin 
Topotecan, a water-soluble, semisynthetic derivative of camptothecin, is a specific 
inhibitor of topoisomerase, and has been most intensively evaluated in recurrent SCLC. 
In the study conducted by Ardizzoni et al., 101 patients were enrolled, and 92 (45 
sensitive and 47 refractory) were assessable for response. Among refractory relapse 
patients, there were 1 CR and 2 PRs, with an overall response rate of 6.4%, whereas in 
sensitive relapse, there were 6 CRs and 11 PRs, for an overall response rate of 37.8%. 
MST of sensitive and refractory relapse patients was 6.9 months and 4.7 months, 
respectively.
62
 Combined with other studies, the overall response rate and MST of 
topotecan were 6.4% to 38% and 6.4 to 8.7 months in sensitive relapse, and 2.4% to 
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6.4% and 4.1 to 5.1 months in refractory relapse, respectively.
62-66
 The results of phase 
II studies of topotecan are summarized in Table 3.
62-66
  
 Von Pawel et al. conducted the first phase III study in patients with recurrent 
SCLC, in which topotecan and CAV were compared. Patients received either topotecan 
(1.5 mg/m
2
) as a 30-minute infusion daily for 5 days every 3 weeks or CAV 
(cyclophosphamide 1,000 mg/m
2
, doxorubicin 45 mg/m
2
, and vincristine 2 mg) infused 
on day 1 every 3 weeks. All patients had relapsed at least 60 days after completion of 
first-line chemotherapy. The response rate, median time to progression (TTP), and MST 
were 24.3%, 13.3 weeks, and 25.0 weeks in the topotecan arm and 18.3%, 12.3 weeks, 
and 24.7 weeks in the CAV arm, respectively (p=0.285 for the response rate, p=0.552 
for TTP, and p=0.795 for MST, respectively). The proportion of patients who 
experienced symptom improvement was greater in the topotecan arm than in the CAV 
arm for 4 of 8 symptoms evaluated, including dyspnea, anorexia, hoarseness, and 
fatigue, as well as interference with daily activity.
67
 The oral formulation of topotecan is 
similar in efficacy and tolerability to IV topotecan, and more convenient than IV 
topotecan.
68,69
 In the phase III study conducted by O’Brien et al., BSC alone and 
BSC+oral topotecan were compared in recurrent SCLC patients who were unsuitable 
for intravenous chemotherapy. In the study, 70 and 71 patients were assigned to BSC 
alone and topotecan group, respectively. There were 7% PR and 44% SD in the 
topotecan group, and MST almost doubled (13.9 weeks vs 25.9 weeks).
70
 This is the 
only randomized study in second-line for relapsed SCLC comparing chemotherapy with 
BSC. Currently, topotecan is the only drug approved by the Food and Drug 
Administration (FDA) for recurrent SCLC. Randomized studies of topotecan are 




 Amrubicin is a totally synthetic 9-aminoanthracycline, (+)-(7S, 
9S)-9-acetyl-9-amino-7-[(2-deoxy-β-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahyd
ro-6,11-dihydroxy-5,12-naphthacenedione hydrochloride, with a chemical structure 
similar to that of doxorubicin. Amrubicin showed more potent antitumor activity than 
doxorubicin in several human tumor xenografts implanted in nude mice.
71
 Acute 
toxicity of amrubicin is qualitatively similar to that of doxorubicin; however, amrubicin 
shows almost no delayed toxicity (e.g. cardiotoxicity).
72-74
 Amrubicin is converted to an 
active metabolite, amrubicinol, by reduction of its C-13 ketone group to a hydroxyl 
group. In vitro cytotoxic activity of amrubicinol was almost equipotent to that of 
doxorubicin and is 20 to 220 times more potent than its parent compound, amrubicin.
75
 
Despite their similarity in chemical structure, amrubicin has a different mode of action 
to doxorubicin. Amrubicin and its active metabolite, amrubicinol, are inhibitors of DNA 
topoisomerase II. In a phase I–II study of patients with non-small cell lung cancer, 
amrubicin was administered as a 5-min intravenous infusion for 3 consecutive days. The 
maximum tolerated dose (MTD) was 50 mg/m
2
/day and the dose-limiting toxicities 
were leukopenia, neutropenia, thrombocytopenia, and gastrointestinal complications. 
The recommended dose in the phase II study was 45 mg/m
2




 As for SCLC, Yana et al. conducted a phase II study on previously untreated 
ED-SCLC. Amrubicin was administered at a dose of 45 mg/m
2
/day intravenously on 
days 1 to 3, every 3 weeks. Of the 33 patients, 3 had CR and 22 had PR, with an overall 
response rate of 75.8%. MST was 11.7 months, and 1-year and 2-year survival rates 
were 48.5% and 20.2%, respectively; however, hematologic toxicities were severe: 





 For relapsed patients, a phase I study was conducted by Okamoto et al. 
Fifteen patients were treated with amrubicin at doses of 30, 35, or 40 mg/m
2
 on 3 
consecutive days every 3 weeks. Grade 4 neutropenia was observed in 67% of patients, 






 Similarly, Igawa et al. conducted a dose-escalating study 
of second-line and third-line settings separately. The recommended doses were 
determined as 40 mg/m
2
 for the second-line setting and 35 mg/m
2




 In Japan, 3 phase II studies have been conducted at different doses of 
amrubicin for relapsed SCLC.  In the first study, conducted by Kato et al., 45 mg/m
2
 of 
amrubicin was administered on days 1–3 every 3 weeks. Thirty-four patients were 
treated with amrubicin, and there were 4 CRs and 14 PRs, with a response rate of 53%. 
The response rate and MST in sensitive relapse and refractory relapse were 50% and 
10.4 months, and 60% and 6.8 months, respectively.
80
 In the second study, conducted by 
Onoda et al., 40 mg/m
2
 of amrubicin was administered on the same schedule and 60 
patients were enrolled. The response rate and MST in sensitive relapse and refractory 
relapse were 52% and 11.6 months, and 50% and 10.3 months, respectively.
10
 The third 
study was conducted by Kaira et al. and 35 mg/m
2
 of amrubicin was administered to 
both SCLC and NSCLC patients. In this study, 29 relapsed SCLC patients were enrolled, 
and the response rate and MST in sensitive relapse and refractory relapse were 60% and 
12.0 months, and 37% and 11.0 months, respectively.
81
 In the first study, grade 4 
neutropenia was noted in 71% of patients; however, the incidence were 55% in the 
second study and 10% in the third study, respectively. Considering that efficacy data 
were almost similar, fewer doses seems to be preferable in relapsed patients, as 
13 
 
indicated in previous phase I studies. Recently, the results of the first phase II study 
conducted outside Japan were presented. In the study, 75 Western patients with 
refractory relapse were treated with 40 mg/m
2
 of amrubicin on 3 consecutive days every 
3 weeks. The response rate and MST were 21% and 6.0 months, respectively.
82
 The 
response rate and survival were considerably lower compared with Japanese phase II 
studies; however, consistent with the results of a Japanese randomized phase II studies 
comparing amrubicin with topotecan.
11
 Table 5 summarizes the phase II studies of 
amrubicin.
10,80-82 
 So far, two randomized phase II studies comparing topotecan and amrubicin 
have been conducted (Table 6).
11,83
 In the first study, conducted in Japan, 60 patients 
were randomly assigned to either amrubicin (40 mg/m
2
 on days 1–3, every 3 weeks) or 
topotecan (1.0 mg/m
2
 on days 1–5, every 3 weeks), and 59 were evaluable. In the study, 
36 sensitive relapse and 23 refractory relapse patients were included. Response rates 
were 13% in the topotecan arm and 38% in the amrubicin arm (p=0.039): in sensitive 
relapse, 21% for the topotecan arm and 53% for the amrubicin arm; in refractory relapse, 
0% for the topotecan arm and 17% for the amrubicin arm. Median progression-free 
survival times (PFSs) and MSTs were 2.2 months and 8.4 months for the topotecan arm, 
and 3.5 months and 8.1 months for the amrubicin arm, respectively. However, many 
patients in the topotecan arm subsequently received amrubicin, and multivariate 
analysis revealed that amrubicin had more impact on overall survival than topotecan. 
There was one treatment-related death resulting from neutropenic infection in the 
amrubicin arm.
11
 In the second study, conducted in the U.S., 76 sensitive relapse 
patients were randomly assigned to either amrubicin (40 mg/m
2
 on days 1–3, every 3 
weeks) or topotecan (1.5 mg/m
2
 on days 1–5, every 3 weeks). The response rate was 
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significantly better in the amrubicin arm (11.5% vs 44%, p=0.005). Median PFSs and 
MSTs were 3.3 months and 7.7 months for the topotecan arm, and 4.6 months and 9.3 
months for the amrubicin arm, respectively. One patient in the topotecan arm and 4 






The c-KIT protein, also known as CD117, is a member of the type III receptor tyrosine 
kinase (TK) family, and previous studies have shown that ~70% SCLC cells express 
c-kit. Imatinib is an orally available small molecule that inhibits several protein TK, 
including c-kit, platelet-derived growth factor receptor (PDGFR), and Bcr-Abl fusion 
protein, and is effective against chronic myeloid leukemia and gastrointestinal stromal 
tumors (GIST). Based on these facts, imatinib has been tested for relapsed SCLC in 
several clinical studies;
84-86
 however, none showed the effectiveness of imatinib. One 
possible explanation is that c-kit expression in SCLC is not correlated with activating 
mutations in c-kit exon 11, which predict the activity of imatinib in GIST. Further 




The microvessel count and vascular endothelial growth factor (VEGF) level were found 
to significantly affect survival in SCLC patients who underwent primary resection 
followed by adjuvant chemotherapy.
88
 These data prompted us to carry out a clinical 
study of anti-angiogenic agents for relapsed SCLC.  
 Bevacizumab is a recombinant, humanized monoclonal antibody against VEGF. 
15 
 
Jalal et al. conducted a phase II study of the combination of paclitaxel and bevacizumab 
for sensitive relapse SCLC. Thirty-four patients were enrolled and preliminary results 
were reported in 27 patients: response rate, 11.1%; SD, 55.5%; PD,33.3%; median PFS, 
13 weeks; and MST, 21 weeks.
89
  
 Cediranib is a highly potent inhibitor of VEGFR-1, -2, and -3 TKs. In the phase 
II study conducted by Ramalingam et al., cediranib was administered at the daily oral 
dose of 45 mg, reduced to 30 mg because of toxicity, to 25 SCLC patients pretreated 
with only 1 previous regimen. Unconfirmed PR was reported in 1 patient and SD in 9 
patients, with median PFS of 8 weeks and MST of 6 months. Cediranib failed to meet 
the predefined target (20% response) to continue full accrual to the study.
90
  
 Sorafenib is a multi-kinase inhibitor affecting the pathways involved in tumor 
progression and angiogenesis, such as Raf-1, VEGFR-2, VEGFR-3, and PDGFR-β. 
Sorafenib was administered at the daily oral total dose of 800 mg in 82 patients with 
SCLC who progressed after 1 platinum-based regimen and were stratified by platinum 
sensitivity. There were 4 PRs (3 sensitive relapse) and 25 SDs (12 sensitive relapse). 
Median PFS was 2 months in both groups, and MSTs were 7 months in sensitive relapse 
and 5 months in refractory relapse, respectively.
91
 Overall, anti-angiogenic agents are 
not promising for SCLC.  
 
Epidermal Growth Factor Receptor Inhibitors 
Gefitinib is an orally active inhibitor selective for the TK of epidermal growth factor 
receptor (EGFR). Although EGFR expression is usually not noted in SCLC cells, there 
have been 2 phase II studies of gefitinib for relapsed SCLC.  
 In the study conducted by Moore et al., 19 patients with SCLC pretreated with 
16 
 
1 or 2 previous treatments received oral gefitinib at a daily dose of 250mg; however, 
there was no complete or partial response.
92
 In another study conducted by Langer et al., 
among 29 patients, only 1 patient achieved PR and the response rate was 3%.
93
 The 
most reliable predictive marker of response with EGFR tyrosine kinase inhibitors, 
including gefitinib, is somatic mutation of the EGFR gene, and the frequency of 
mutation is exclusively high in adenocarcinoma histology.
94
 Although mutation data are 
lacking for SCLC, further studies of EGFR inhibitors are not warranted. 
 
Farnesyl Transferase Inhibitor 
Ras is a protein requiring farnesylation before it can mediate its proliferative functions, 
which is critical in carcinogenic processes. Tipifarnib is an oral non-peptidomimetic 
farnesyl transferase inhibitor that blocks the activity of farnesylated proteins involved in 
the signal transduction pathways critical for cell proliferation and survival. Heymach et 
al. conducted a phase II study of single-agent tipifarnib. Twenty-two sensitive relapse 
patients were enrolled; however, no significant antitumor activity was noted.
95
 One 
possible explanation for the lack of sensitivity to tipifarnib is the absence of activating 
Ras mutations in SCLC cells.  
 
Conclusions 
A large number of clinical studies of relapsed SCLC have been conducted; however, 
treatment advances are slow. In addition, no targeted agents have proved effective, 
unlike in NSCLC. Better understanding of the molecular mechanisms is clearly needed, 
but amrubicin is the most promising at present. A Phase III study comparing amrubicin 




1. Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer 
in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results 
database. J Clin Oncol 2006; 24: 4539-44. 
2. Postmus PE, Smit EF. Treatment of relapsed small cell lung cancer. Semin Oncol 2001; 28: 
48-52. 
3. Giaccone G, Donadio M, Bonardi G et al. Teniposide in the treatment of small-cell lung cancer: 
the influence of prior chemotherapy. J Clin Oncol 1988; 6: 1264-70. 
4. Ebi N, Kubota K, Nishiwaki Y et al. Second-line chemotherapy for relapsed small cell lung 
cancer. Jpn J Clin Oncol 1997; 27: 166-9. 
5. Rosti G, Bevilacqua G, Bidoli P et al. Small cell lung cancer. Ann Oncol 2006; 17 Suppl 2: 
ii5-10. 
6. Giaccone G, Ferrati P, Donadio M et al. Reinduction chemotherapy in small cell lung cancer. 
Eur J Cancer Clin Oncol 1987; 23: 1697-9. 
7. Postmus PE, Berendsen HH, van Zandwijk N et al. Retreatment with the induction regimen in 
small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin 
Oncol 1987; 23: 1409-11. 
8. Glisson BS. Recurrent small cell lung cancer: update. Semin Oncol 2003; 30: 72-78. 
9. Ardizzoni A. Topotecan in the treatment of recurrent small cell lung cancer: an update. 
Oncologist 2004; 9 Suppl 6: 4-13. 
10. Onoda S, Masuda N, Seto T et al. Phase II trial of amrubicin for treatment of refractory or 
relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006; 24: 
5448-53. 
11. Inoue A, Sugawara S, Yamazaki K et al. Randomized phase II trial comparing amrubicin with 
topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study 
Group Trial 0402. J Clin Oncol 2008; 26: 5401-6. 
12. Evans WK, Feld R, Osoba D et al. VP-16 alone and in combination with cisplatin in previously 
treated patients with small cell lung cancer. Cancer 1984; 53: 1461-6. 
13. Wolff SN, Birch R, Sarma P, Greco FA. Randomized dose-response evaluation of etoposide in 
small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986; 70: 
583-7. 
14. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide 
plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85-91. 
15. Hanna N, Bunn PA, Jr., Langer C et al. Randomized phase III trial comparing 
irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease 
18 
 
small-cell lung cancer. J Clin Oncol 2006; 24: 2038-43. 
16. Lara PN, Jr., Natale R, Crowley J et al. Phase III trial of irinotecan/cisplatin compared with 
etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from 
SWOG S0124. J Clin Oncol 2009; 27: 2530-5. 
17. Masuda N, Fukuoka M, Kusunoki Y et al. CPT-11: a new derivative of camptothecin for the 
treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10: 1225-9. 
18. Pallis AG, Agelidou A, Agelaki S et al. A multicenter randomized phase II study of the 
irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with 
extensive stage small-cell lung cancer. Lung Cancer 2009; 65: 187-91. 
19. Yamori T, Sato S, Chikazawa H, Kadota T. Anti-tumor efficacy of paclitaxel against human 
lung cancer xenografts. Jpn J Cancer Res 1997; 88: 1205-10. 
20. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients 
with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin 
Oncol 1995; 13: 1430-5. 
21. Smit EF, Fokkema E, Biesma B et al. A phase II study of paclitaxel in heavily pretreated 
patients with small-cell lung cancer. Br J Cancer 1998; 77: 347-51. 
22. Hoang T, Kim K, Jaslowski A et al. Phase II study of second-line gemcitabine in sensitive or 
refractory small cell lung cancer. Lung Cancer 2003; 42: 97-102. 
23. Chan DC, Chen VJ, Zhang Z et al. Studies of pemetrexed and gemcitabine, alone and in 
combinations, in human lung cancer models. ASCO Meeting Abstracts 2006; 24: 17114. 
24. Jalal S, Ansari R, Govindan R et al. Pemetrexed in second line and beyond small cell lung 
cancer: a Hoosier Oncology Group phase II study. J Thorac Oncol 2009; 4: 93-6. 
25. Gronberg BH, Bremnes RM, Aasebo U et al. A prospective phase II study: high-dose 
pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer 2009; 63: 88-93. 
26. Socinski MA, Smit EF, Lorigan P et al. Phase III study of pemetrexed plus carboplatin 
compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell 
lung cancer. J Clin Oncol 2009; 27: 4787-92. 
27. Eckardt JR, Bentsion DL, Lipatov ON et al. Phase II study of picoplatin as 
second-line therapy for patients with small-cell lung cancer. J Clin Oncol 2009;27:2046-51. 
28. Planting AS, Splinter TA, Ardizzoni A et al. Phase II study of ACNU as second-line treatment 
in small-cell lung cancer. EORTC Lung Cancer Cooperative Group. Cancer Chemother Pharmacol 1992; 
29: 409-11. 
29. Ardizzoni A, Antonelli G, Ricci S et al. Ambamustine in the second-line treatment of patients 
with small-cell lung cancer: a phase II Fonicap study. Am J Clin Oncol 2000; 23: 22-5. 
30. Sessa C, Wanders J, Roelvink M et al. Second-line treatment of small-cell lung cancer with the 
camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG). Ann 
19 
 
Oncol 2000; 11: 207-10. 
31. Samantas E, Kalofonos H, Linardou H et al. Phase II study of pegylated liposomal 
doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study. 
Ann Oncol 2000; 11: 1395-7. 
32. Schmittel A, Knodler M, Hortig P et al. Phase II trial of second-line bendamustine 
chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 2007; 55: 109-13. 
33. Eisen T, Thatcher N, Leyvraz S et al. Phase II study of weekly plitidepsin as second-line 
therapy for small cell lung cancer. Lung Cancer 2009; 64: 60-5. 
34. Evans WK, Osoba D, Feld R et al. Etoposide (VP-16) and cisplatin: an effective treatment for 
relapse in small-cell lung cancer. J Clin Oncol 1985; 3: 65-71. 
35. Figoli F, Veronesi A, Ardizzoni A et al. Cisplatin and etoposide as second-line chemotherapy in 
patients with small cell lung cancer. Cancer Invest 1988; 6: 1-5. 
36. Masuda N, Fukuoka M, Matsui K et al. Evaluation of high-dose etoposide combined with 
cisplatin for treating relapsed small cell lung cancer. Cancer 1990; 65: 2635-40. 
37. Batist G, Carney DN, Cowan KH et al. Etoposide (VP-16) and cisplatin in previously treated 
small-cell lung cancer: clinical trial and in vitro correlates. J Clin Oncol 1986; 4: 982-6. 
38. Porter LL, 3rd, Johnson DH, Hainsworth JD et al. Cisplatin and etoposide combination 
chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat Rep 1985; 69: 479-81. 
39. Sculier JP, Lafitte JJ, Lecomte J et al. A phase II randomised trial comparing the 
cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for 
small-cell lung cancer. Ann Oncol 2002; 13: 1454-9. 
40. Ando M, Kobayashi K, Yoshimura A et al. Weekly administration of irinotecan (CPT-11) plus 
cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 2004; 44: 121-7. 
41. Naka N, Kawahara M, Okishio K et al. Phase II study of weekly irinotecan and carboplatin for 
refractory or relapsed small-cell lung cancer. Lung Cancer 2002; 37: 319-23. 
42. Hirose T, Horichi N, Ohmori T et al. Phase II study of irinotecan and carboplatin in patients 
with the refractory or relapsed small cell lung cancer. Lung Cancer 2003; 40: 333-8. 
43. Masuda N, Matsui K, Negoro S et al. Combination of irinotecan and etoposide for treatment of 
refractory or relapsed small-cell lung cancer. J Clin Oncol 1998; 16: 3329-34. 
44. Schuette W, Nagel S, Juergens S et al. Phase II trial of gemcitabine/irinotecan in refractory or 
relapsed small-cell lung cancer. Clin Lung Cancer 2005; 7: 133-7. 
45. Rocha-Lima CM, Herndon JE 2nd, Lee ME et al. Phase II trial of irinotecan/gemcitabine as 
second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B 
Study 39902. Ann Oncol 2007; 18: 331-7. 
46. Goto K, Sekine I, Nishiwaki Y et al. Multi-institutional phase II trial of irinotecan, cisplatin, 
and etoposide for sensitive relapsed small-cell lung cancer. Br J Cancer 2004; 91: 659-65. 
20 
 
47. Kim Y, Goto K, Nishiwaki Y et al. Phase II study of weekly cisplatin, etoposide and irinotecan 
(PE/CPT) for refractory relapsed small cell lung cancer (SCLC). ASCO Meeting Abstracts 2006; 24: 
7088. 
48. Groen HJ, Fokkema E, Biesma B et al. Paclitaxel and carboplatin in the treatment of small-cell 
lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant 
schedule. J Clin Oncol 1999; 17: 927-32. 
49. Kakolyris S, Mavroudis D, Tsavaris N et al. Paclitaxel in combination with carboplatin as 
salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. Ann Oncol 
2001; 12: 193-7. 
50. Roth BJ, Johnson DH, Einhorn LH et al. Randomized study of cyclophosphamide, doxorubicin, 
and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive 
small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 
282-91. 
51. Postmus PE, Smit EF, Berendsen HH, Haaxma-Reiche H. Second-line carboplatin-based 
chemotherapy for small cell lung cancer: the Groningen experience. Semin Oncol 1992; 19: 17-23. 
52. Postmus PE, Smit EF, Kirkpatrick A, Splinter TA. Testing the possible non-cross resistance of 
two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of 
the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1993; 29A: 204-7. 
53. Falk SJ, Maughan TS, Laurence VM et al. Phase II study of carboplatin and adriamycin as 
second line chemotherapy in small cell lung cancer. Clin Oncol (R Coll Radiol) 1993; 5: 85-8. 
54. Faylona EA, Loehrer PJ, Ansari R et al. Phase II study of daily oral etoposide plus ifosfamide 
plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial. J 
Clin Oncol 1995; 13: 1209-14. 
55. Kubota K, Nishiwaki Y, Kakinuma R et al. Dose-intensive weekly chemotherapy for treatment 
of relapsed small-cell lung cancer. J Clin Oncol 1997; 15: 292-6. 
56. Ichiki M, Gohara R, Rikimaru T et al. Combination Chemotherapy with Irinotecan and 
Ifosfamide as Second-Line Treatment of Refractory or Sensitive Relapsed Small Cell Lung Cancer: A 
Phase II Study. Chemotherapy 2002; 49: 200-5. 
57. Sonpavde G, Ansari R, Walker P et al. Phase II study of doxorubicin and paclitaxel as 
second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial. Am J Clin Oncol 
2000; 23: 68-70. 
58. Kosmas C, Tsavaris NB, Malamos NA et al. Phase II study of paclitaxel, ifosfamide, and 
cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol 2001; 19: 119-26. 
59. Isobe K, Kobayashi K, Kosaihira S et al. Phase II study of nimustine hydrochloride (ACNU) 
plus paclitaxel for refractory small cell lung cancer. Lung Cancer 2009; 66: 350-4. 
60. Dongiovanni V, Buffoni L, Berruti A et al. Second-line chemotherapy with weekly paclitaxel 
21 
 
and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single 
institution phase II trial. Cancer Chemother Pharmacol 2006; 58: 203-9. 
61. Leighl NB, Goss GD, Lopez PG et al. Phase II study of pegylated liposomal doxorubicin HCl 
(Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with 
small cell lung cancer. Lung Cancer 2006; 52: 327-32. 
62. Ardizzoni A, Hansen H, Dombernowsky P et al. Topotecan, a new active drug in the 
second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive 
disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group 
and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997; 15: 
2090-6. 
63. Eckardt J, Gralla R, Palmer MC et al. Topotecan (T) as second-line therapy in patients (Pts) 
with small cell lung cancer (SCLC): a phase II study. Ann Oncol 1996; 7(suppl 5): 107. 
64. Depierre A, von Pawel J, Hans K et al. Evaluation of topotecan (HycamtinTM) in relapsed small 
cell lung cancer (SCLC). A multicentre phase II study. Lung Cancer 1997; 18(suppl 1): 35. 
65. Takeda K, Negoro S, Sawa T et al. A phase II study of topotecan in patients with relapsed 
small-cell lung cancer. Clin Lung Cancer 2003; 4: 224-8. 
66. Perez-Soler R, Glisson BS, Lee JS et al. Treatment of patients with small-cell lung cancer 
refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996; 14: 
2785-90. 
67. von Pawel J, Schiller JH, Shepherd FA et al. Topotecan versus cyclophosphamide, doxorubicin, 
and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17: 658-67. 
68. von Pawel J, Gatzemeier U, Pujol JL et al. Phase ii comparator study of oral versus intravenous 
topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001; 19: 1743-9. 
69. Eckardt JR, von Pawel J, Pujol JL et al. Phase III study of oral compared with intravenous 
topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007; 25: 2086-92. 
70. O'Brien ME, Ciuleanu TE, Tsekov H et al. Phase III trial comparing supportive care alone with 
supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 
24: 5441-7. 
71. Morisada S, Yanagi Y, Noguchi T et al. Antitumor activities of a novel 9-aminoanthracycline 
(SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 1989; 80: 
69-76. 
72. Morisada S, Yanagi Y, Kashiwazaki Y, Fukui M. Toxicological aspects of a novel 
9-aminoanthracycline, SM-5887. Jpn J Cancer Res 1989; 80: 77-82. 
73. Suzuki T, Minamide S, Iwasaki T et al. Cardiotoxicity of a new anthracycline derivative 
(SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest 
New Drugs 1997; 15: 219-25. 
22 
 
74. Noda T, Watanabe T, Kohda A et al. Chronic effects of a novel synthetic anthracycline 
derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest 
New Drugs 1998; 16: 121-8. 
75. Yamaoka T, Hanada M, Ichii S et al. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, 
and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 1998; 89: 1067-73. 
76. Negoro S, Fukuoka M, Nakamura S, Ikegami H, Sugiura T, Ariyoshi Y. Phase I-II study of 
amrubicin (SM-5887), a novel 9-aminoanthracycline, by iv administration for 3 consecutive days in 
patients with advanced non-small-cell lung cancer. ASCO Meeting Abstracts 1995; 14: 361. 
77. Yana T, Negoro S, Takada M et al. Phase II study of amrubicin in previously untreated patients 
with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. 
Invest New Drugs 2007; 25: 253-8. 
78. Okamoto I, Hamada A, Matsunaga Y et al. Phase I and pharmacokinetic study of amrubicin, a 
synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. Cancer Chemother 
Pharmacol 2006; 57: 282-8. 
79. Igawa S, Yamamoto N, Ueda S et al. Evaluation of the recommended dose and efficacy of 
amrubicin as second- and third-line chemotherapy for small cell lung cancer. J Thorac Oncol 2007; 2: 
741-4. 
80. Kato T, Nokihara H, Ohe Y et al. Phase II trial of amrubicin in patients with previously treated 
small cell lung cancer (SCLC). ASCO Meeting Abstracts 2006; 24: 7061. 
81. Kaira K, Sunaga N, Tomizawa Y et al. A phase II study of amrubicin, a synthetic 
9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer 2009 (in press). 
82. Ettinger DS, Jotte R, Lorigan P et al. Phase II study of amrubicin as second-line therapy in 
patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010; 28: 2098-603. 
83. Jotte R, Conkling P, Reynolds C et al. Results of a randomized phase II trial of amrubicin 
(AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) 
sensitive to first-line platinum-based chemotherapy. ASCO Meeting Abstracts 2009; 27: 8028. 
84. Johnson BE, Fischer T, Fischer B et al. Phase II study of imatinib in patients with small cell 
lung cancer. Clin Cancer Res 2003; 9: 5880-87. 
85. Dy GK, Miller AA, Mandrekar SJ et al. A phase II trial of imatinib (ST1571) in patients with 
c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005; 16: 
1811-6. 
86. Krug LM, Crapanzano JP, Azzoli CG et al. Imatinib mesylate lacks activity in small cell lung 
carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 2005; 103: 2128-31. 
87. Burger H, den Bakker MA, Stoter G et al. Lack of c-kit exon 11 activating mutations in 
c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer 2003; 39: 793-9. 
88. Lucchi M, Mussi A, Fontanini G et al. Small cell lung carcinoma (SCLC): the angiogenic 
23 
 
phenomenon. Eur J Cardiothorac Surg 2002; 21: 1105-10. 
89. Jalal SI, Bhatia S, Einhorn LH et al. Paclitaxel (P) plus bevacizumab (B) in patients (pts) with 
chemosensitive relapsed small cell lung cancer (SCLC): A safety, feasibility and efficacy trial from the 
Hoosier Oncology Group. ASCO Meeting Abstracts 2008; 26: 19013. 
90. Ramalingam SS, Mack PC, Vokes EE et al. Cediranib (AZD2171) for the treatment of recurrent 
small cell lung cancer (SCLC): A California Consortium phase II study (NCI # 7097). ASCO Meeting 
Abstracts 2008; 26: 8078. 
91. Gitlitz BJ, Glisson BS, Moon J, Reimers H, Gandara DR. Sorafenib in patients with platinum 
(plat) treated extensive stage small cell lung cancer (E-SCLC): A SWOG (S0435) phase II trial. ASCO 
Meeting Abstracts 2008; 26: 8039. 
92. Moore AM, Einhorn LH, Estes D et al. Gefitinib in patients with chemo-sensitive and 
chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 
2006; 52: 93-7. 
93. Langer SW, Pedersen BS, Ranson M, Pappot H, Loft A, Thatcher N. PHASE II STUDY OF 
IRESSA (GEFITINIB) IN RELAPSED AND REFRACTORY SMALL CELL LUNG CANCER (SCLC). 
J Thorac Oncol 2008; 3: S55. 
94. Jiang H. Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin 
Oncol 2009; 39: 137-50. 
95. Heymach JV, Johnson DH, Khuri FR et al. Phase II study of the farnesyl transferase inhibitor 










Table 1 Prospective studies of single-agent chemotherapy for relapsed SCLC 
Regimen n* refractoy pts RR  RR in refractory pts  MST  MST (months) 
  (%) (%) (%) (months) sensitive/refractory 
Etoposide12 14 NA 7 NA 2.0 NA 
Etoposide13 77 NA 6 NA 4.4 NA 
Teniposide3 44 NA 34 NA 6.9 NA 
Irinotecan17 15 7 47 NA 6.2 NA 
Irinotecan18 31 64 0 0 4.6  8.6 / 3.8  
ACNU28 23 NA 4 NA NA NA 
Paclitaxel21 24 NA 29 NA 3.3 NA 
Ambamustine29 17 71 0 0 3.9 NA 
GI14721130 62 45 17 10 NA NA 
Caelyx31 14 NA 0 0 NA NA 
Gemcitabine22 27 44 0 0 6.4  8.8 / 4.2  
Bendamustine32 21 NA 29 NA 7.0  NA 
Pemetrexed24 43 53 5 4 3.5  4.4 / 2.7  
Pemetrexed25 34 26 3 11 4.1 5.3 / 3.6 
Plitidepsin33 20 NA 0 0 4.8  NA 
Picoplatin27 77 92 4 NA 5.2  NA 
*number of evaluable patients for response 
pts, patients; RR, response rate; MST, median survival time; NA, not available 
 
Table 2 Prospective studies of combination chemotherapy for relapsed SCLC 
Regimen n* Refractory  
pts 
RR RR in refractory  
pts 
MST MST (months) 
  (%) (%) (%) (months)  sensitive/refractory 
CDDP+ETP12 34 NA 44 NA 4.0 NA 
CDDP+ETP34 78 NA 55 NA NA NA 
CDDP+ETP35 27 NA 41 NA 6.5 NA 
CDDP+ETP36 18 NA 50 NA 4.7 NA 
CDDP+ETP37 29 NA 12 NA 3.0  NA 
CDDP+ETP38 29 100 52 52 NA NA 
CDDP+ETP39 31 52 29 19 4.3  NA 
CDDP+ETP50 59 46 22 15 NA NA 
CBDCA+VCR51 22 NA 36 NA 4.2 NA 
VIMP51 19 NA 53 NA 4.7 NA 
VIMP52 25 NA 60 NA 4.4 NA 
CPA+DXR+ETP52 43 NA 51 NA 5.1 NA 
CBDCA+DXR53 25 NA 64 NA 5.4 NA 
CDDP+ETP+IFM54 42 NA 55 NA 6.8 NA 
CODE55 17 NA 88 NA 8.2 NA 
CDDP+CPT-1140 25 64 80 81 7.9 NA 
CBDCA+CPT-1141 29 45 31 23 6.1 6.1 / 5.7  
CBDCA+CPT-1142 22 41 68 33 6.5 8.2 / 6.5 
ETP+CPT-1143 25 16 71 75 9.0 NA 
IFM+CPT-1156 34 29 53 33 7.2  NA 
GEM+CPT-1144 35 43 17 27 5.8  8.7 / 4.5  
GEM+CPT-1145 71 50 21 11 NA 7.1 / 3.1  
GEM+CPT-1118 38 47 24 11 6.8  8.6 / 5.7  
DXR+PTX57 46 30 41 14 5.8 NA 
CBDCA+PTX48 34 NA 74 NA 7.2 NA 
CBDCA+PTX49 32 100 25 25 7.0  - / 7.0  
CDDP+PTX+IFM58 33 61 73 70 6.5 NA 
CDDP+ETP+CPT-1146 40 0 78 - 11.8  11.8 / - 
CDDP+ETP+CPT-1147 30 100 70 70 7.3  - / 7.3  
ACNU59 24 100 25 25 5.8  NA 
PTX+GEM60 31 32 26 20 7.5 8.3 / 2.5 
Caelyx+CPA+VCR61 31 29 10 NA 6.5 NA 
*number of evaluable patients for response 
pts, patients; RR, response rate; MST, median survival time; CDDP, cisplatin; ETP, etoposide; CBDCA, carboplatin; VCR, 
vincristine; VIMP, vincristine+ifosfamide+mesna+carboplatin; CPA, cyclophosphamide; DXR, doxorubicin; DXR, doxorubicin; 
IFM, ifosfamide; CODE, cisplatin+vincristine+doxorubicin+etoposide; CPT-11, irinotecan; GEM, gemcitabine; PTX, paclitaxel 
Table 3 Phase II studies of single-agent topotecan for relapsed SCLC 
Study Phase Chemosensitivity n Response rate (%) MST (months) 
Ardizzoni et al.62 II S 45 37.8 6.9  
  R 47 6.4 4.7  
Eckardt et al.63 II S 36 19.0 6.2 
  R 38 3.0 4.8 
Depierre et al.64 II S 57 14.0 6.0 
  R 41 2.4 3.8 
Takeda et al.65 II S 50 26.0 8.7 
  R 0 - - 
Perez-Soler et al.66 II S 0 - - 
  R 32 11.0 4.7 
MST, median survival time; S, sensitive; R, refractory 
Table 4 Randomized studies of single-agent topotecan for relapsed SCLC 
Study Phase Regimen n Response rate (%) MST (weeks) 
von Pawel et al.68 II Oral topotecan 52 23.0 32.0 
  IV topotecan 54 15.0 25.0 
Eckardt et al.69 III Oral topotecan 153 18.3 33.0 
  IV topotecan 151 21.9 35.0 
O’Brien et al.70 III BSC 67 - 13.9 
  topotecan 70 7.0 25.9 
von Pawel et al.67 III CAV 104 18.3 24.7 
  topotecan 107 24.3 25.0 
MST, median survival time 
Table 5 Phase II studies of single-agent amrubicin for relapsed SCLC 
Study Phase Dose (mg/m2) Chemosensitivity n Response rate (%) MST (months) 
Kato et al.80 II 45 S 24 50.0 10.4 
   R 10 60.0 6.8 
Onoda et al.10 II 40 S 44 52.0 11.6 
   R 16 50.0 10.3  
Kaira et al.81 II 35 S 10 60.0 12.0 
   R 19 36.8 11.0 
Ettinger et al.82 II 40 S 0 - - 
   R 75 21.0 6.0  
MST, median survival time; S, sensitive; R, refractory 
Table 6 Randomized phase II studies comparing topotecan and amrubicin for relapsed SCLC 






Inoue et al.11 topotecan S 19 21.0 3.0  11.7  
  R 11 0.0 1.5  5.4  
 amrubicin S 17 53.0 3.9  9.9 
  R 12 17.0 2.6  5.3  
Jotte et al.83 topotecan S 26 11.5 3.3  7.7  
  R - - - - 
 amrubicin S 50 44.0 4.6  9.3  
  R - - - - 
PFS, progression-free survival; OS, overall survival; S, sensitive; R, refractory 
